

Genetic Toxicology

Sequani is a UK based CRO with its heritage dating back to over 40 years ago where we are at the forefront of pharmaceutical and biotechnology product developments. Bursting with experience, excellence and expertise, we take pride in offering superior value for money, greater flexibility and speed of response- turning data into decisions and defining the way forward. We thrive upon joining our clients upon their mission to achieve high quality data derived by undertaking each project to the highest regulatory standard. Our flexibility, adaptability, strategic programme management and scientific rigour guarantees our customer satisfaction.

- > **Comprehensive selection of genetic toxicity studies**
- > **Screening studies to support discovery phases**
- > **In vitro and in vivo**

Genetic toxicology testing forms an integral part of safety assessment. Sequani has significant experience in performing regulatory genetic toxicology studies and early screening assays in order to fully identify the genotoxic potential of any compound.

Sequani Limited
Bromyard Road, Ledbury, HR8 1LH, United Kingdom

> **website:** www.sequani.com

> **phone:** +44 (0)1531 634121


sequani
NON CLINICAL

great people, great work, real results

Genetic Toxicology

At Sequani, we pride ourselves on being one of the earliest adoptors of the in vitro micronucleus test using flow cytometry as well as offering the following regulatory genetic toxicology services:

STUDY TYPES

Bacterial Reverse Mutation Test	Ames Test
Gene Mutation in Mammalian Cells	L5178Y TK± Mouse Lymphoma Assay (MLA)
Chromosome Aberration	Human Lymphocytes (HL)
In vitro Micronucleus	TK6 Cells Flow-Cytometric Measurement
In vivo Rodent Micronucleus Test	<ul style="list-style-type: none">- Mouse peripheral blood and bone marrow- Rat peripheral blood and bone marrow- Flow cytometric measurement- Combination with repeat-dose toxicity

SCREENING STUDIES

Assessing genotoxicity potential during the discovery phase can add significant value in de-risking product development. As part of our growing lead candidate selection service, Sequani offers “screens” to aid the decision making process. These screens are deliberate cut-down, non-GLP, screening versions of our in vitro genetic toxicology studies. These screening studies offer numerous advantages:

- Multiple compounds or analogues tested at once
- Fast turnaround of results
- Early genotoxic hazard identification
- Low compound requirement <0.5g
- Reduced cost

Sequani can offer bespoke packages at competitive prices to suit your needs. For further information, please contact:

business.development@sequani.com

For further details, see our extended service profile at www.sequani.com

Sequani Limited
Bromyard Road, Ledbury, HR8 1LH, United Kingdom

> **website:** www.sequani.com

> **phone:** +44 (0)1531 634121

